Sophiris’s prostate drug meets main goal in late-stage study

(Reuters) - Sophiris Bio Inc said on Tuesday its sole drug in development met the main goal of a late stage study, reviving hopes for approval 11 months after the company's interim analysis suggested the treatment would fail the study. The company said the drug, PRX302, had significantly improved symptoms in men suffering from benign prostatic hyperplasia, or enlarged prostate. The company, which has been developing PRX302 since 2009, said in December that an interim analysis had showed the treatment would not be effective, based on data available at that time.